Condition
Tuberculosis, Meningeal
Total Trials
5
Recruiting
1
Active
1
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
25%
1 of 4 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
5Total
P 1 (1)
P 2 (4)
Trial Status
Completed4
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06446245Phase 2RecruitingPrimary
Adjunctive Doxycycline for Central Nervous System Tuberculosis
NCT04021121Phase 2CompletedPrimary
Adjunctive Linezolid for the Treatment of Tuberculous Meningitis
NCT03537495Phase 2CompletedPrimary
Pharmacokinetic Study of Linezolid for TB Meningitis
NCT02958709Phase 1CompletedPrimary
Optimizing Treatment to Improve TBM Outcomes in Children
NCT02169882Phase 2CompletedPrimary
High-dose Rifampicin for the Treatment of Tuberculous Meningitis: a Dose-finding Study
Showing all 5 trials